Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers

News

Recent Press Releases Archives

Recent Press Releases

2018 News Releases

December 17, 2018 - Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
Read

December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

December 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 3, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

November 7, 2018 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

November 1, 2018 - Puma Biotechnology Reports Third Quarter 2018 Financial Results
Read

October 18, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

October 10, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

October 2, 2018 - Puma Biotechnology’s Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China
Read

September 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference
Read

September 6, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

September 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology’s NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer
Read

August 9, 2018 - Puma Biotechnology Reports Second Quarter 2018 Financial Results
Read

July 31, 2018 - Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada
Read

July 26, 2018 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

July 17, 2018 - Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)
Read

June 29, 2018 - Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

June 26, 2018 - Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

June 2, 2018 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting
Read

May 30, 2018 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference
Read

May 9, 2018 - Puma Biotechnology Reports First Quarter 2018 Financial Results
Read

May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018
Read

April 25, 2018 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

April 3, 2018 - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Read

April 2, 2018 - NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination with Capecitabine or Paclitaxel as Treatment Options for Patients with Breast Cancer Brain Metastases
Read

March 6, 2018 - Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference
Read

March 1, 2018 - Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
Read

February 23, 2018 - Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

February 15, 2018 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read

February 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
Read

February 1, 2018 - Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China
Read

January 31, 2018 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers - Data published online today in Nature -
Read

January 30, 2018 - Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel
Read

January 29, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

January 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read




Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax